sorafenib amorphous (DPH001)
/ Disruptive Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 17, 2025
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: Disruptive Pharma | Active, not recruiting ➔ Completed
Trial completion
March 10, 2025
A Phase 1 Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (Sorafenib) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=12 | Active, not recruiting | Sponsor: Disruptive Pharma | Not yet recruiting ➔ Active, not recruiting
Enrollment closed
1 to 2
Of
2
Go to page
1